Novartis AG Total Current Assets 2010-2024 | NVS

Novartis AG total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
  • Novartis AG total current assets for the quarter ending September 30, 2024 were $31.264B, a 31.53% decline year-over-year.
  • Novartis AG total current assets for 2023 were $30.481B, a 17.42% decline from 2022.
  • Novartis AG total current assets for 2022 were $36.91B, a 19.27% decline from 2021.
  • Novartis AG total current assets for 2021 were $45.718B, a 54.07% increase from 2020.
Novartis AG Annual Total Current Assets
(Millions of US $)
2023 $30,481
2022 $36,910
2021 $45,718
2020 $29,673
2019 $29,504
2018 $35,563
2017 $28,208
2016 $24,931
2015 $22,845
2014 $37,561
2013 $30,542
2012 $28,004
2011 $24,084
2010 $26,685
2009 $33,691
Novartis AG Quarterly Total Current Assets
(Millions of US $)
2024-09-30 $31,264
2024-06-30 $25,693
2024-03-31 $26,447
2023-12-31 $30,481
2023-09-30 $45,660
2023-06-30 $33,493
2023-03-31 $32,114
2022-12-31 $36,910
2022-09-30 $36,954
2022-06-30 $38,142
2022-03-31 $37,236
2021-12-31 $45,718
2021-09-30 $26,253
2021-06-30 $23,808
2021-03-31 $22,198
2020-12-31 $29,673
2020-09-30 $28,973
2020-06-30 $23,882
2020-03-31 $23,098
2019-12-31 $29,504
2019-09-30 $26,675
2019-06-30 $28,320
2019-03-31 $52,448
2018-12-31 $35,563
2018-09-30 $34,113
2018-06-30 $32,065
2018-03-31 $33,051
2017-12-31 $28,208
2017-09-30 $27,466
2017-06-30 $26,538
2017-03-31 $25,766
2016-12-31 $24,931
2016-09-30 $25,883
2016-06-30 $23,722
2016-03-31 $22,993
2015-12-31 $22,845
2015-09-30 $24,045
2015-06-30 $24,746
2015-03-31 $25,710
2014-12-31 $37,561
2014-09-30 $36,788
2014-06-30 $34,973
2014-03-31 $29,688
2013-12-31 $30,542
2013-09-30 $28,770
2013-06-30 $26,845
2013-03-31 $26,795
2012-12-31 $28,004
2012-09-30 $26,148
2012-06-30 $26,122
2012-03-31 $25,787
2011-12-31 $24,084
2011-09-30 $25,563
2011-06-30 $26,629
2011-03-31 $29,100
2010-12-31 $26,685
2010-09-30 $27,716
2010-06-30 $38,667
2010-03-31 $35,800
2009-12-31 $33,691
2009-09-30 $30,440
2009-06-30 $27,172
2009-03-31 $22,482
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $211.084B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94